List of Excipients in Branded Drug TRIAMTERENE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	TRIAMTERENE	triamterene	66993-831	D&C RED NO. 33
Prasco Laboratories	TRIAMTERENE	triamterene	66993-831	FD&C YELLOW NO. 6
Prasco Laboratories	TRIAMTERENE	triamterene	66993-831	GELATIN
Prasco Laboratories	TRIAMTERENE	triamterene	66993-831	LACTOSE

Generic Drugs Containing TRIAMTERENE

Company	Ingredient	NDC	Excipient
TRUPHARMA LLC	triamterene capsules	52817-364	D&C RED NO. 33
TRUPHARMA LLC	triamterene capsules	52817-364	FD&C YELLOW NO. 6
TRUPHARMA LLC	triamterene capsules	52817-364	GELATIN
TRUPHARMA LLC	triamterene capsules	52817-364	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in TRIAMTERENE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
2	D&C RED NO. 33
2	FD&C YELLOW NO. 6
1	FERRIC OXIDE RED

Excipient Strategy and Commercial Opportunities for Triamterene

Last updated: February 26, 2026

What is the role of excipients in triampterene formulations?

Excipients in triampterene formulations serve to enhance stability, improve bioavailability, facilitate manufacturing, and ensure proper drug delivery. Key excipients include fillers (lactose, microcrystalline cellulose), binders, disintegrants, lubricants (magnesium stearate), and coatings. The choice impacts manufacturing consistency, shelf life, and patient compliance.

How do excipient choices influence tablet stability and bioavailability?

Excipients affect triampterene's pharmacokinetics and shelf stability. For example:

• Lactose monohydrate prevents moisture uptake but may cause hypersensitivity in lactose-intolerant patients.
• Microcrystalline cellulose provides structural integrity and controlled disintegration.
• Disintegrants like croscarmellose sodium optimize dissolution rate, influencing absorption.
• Lubricants ensure smooth manufacturing and prevent sticking.
• Coatings (e.g., film coats) can improve stability against environmental factors and mask taste.

The selection balances manufacturability with patient safety and pharmacological performance.

What are current trends in excipient innovation relevant to triampterene?

Emerging technologies focus on:

• Modified-release systems: Using hydrophilic matrix excipients (e.g., hydroxypropyl methylcellulose) to extend duration of action.
• Low-humidity excipients: To improve stability in climates with high moisture.
• Orodispersible formulations: Employing fast-disintegrating excipients (e.g., maltodextrin, cross-linked polyvinylpyrrolidone) to increase compliance.

What are the key commercial opportunities linked to excipient strategies?

1. Formulation differentiation: Developing controlled-release or dispersible tablets addresses niche markets and competitive advantages.
2. Patent protection: Novel excipient combinations or delivery systems can extend exclusivity.
3. Patent filing: Innovations in excipient composition or manufacturing processes can create barriers to generic entry.
4. Partnerships: Collaborations with excipient manufacturers to develop tailored formulations.
5. Global market expansion: Customizing formulations with excipients compatible with different climates and patient preferences improves market access.

What regulatory considerations affect excipient use in triampterene formulations?

Regulatory agencies (e.g., FDA, EMA) require excipients to be Generally Recognized As Safe (GRAS) and compliant with pharmacopeial standards. New excipients or novel combinations trigger additional review. Documentation must include:

• GRAS status verification.
• Chemical and toxicological data.
• Fit-for-purpose validation.

Changes to excipient composition in existing formulations may require supplemental approval.

How do the excipient trends create opportunities for pharmaceutical companies?

Companies that invest in innovative excipient systems can:

• Enhance product stability and performance.
• Reduce manufacturing costs via streamlined processes.
• Expand into emerging markets with formulations tailored to regional climatic and cultural needs.
• Build patent portfolios around excipient combinations and delivery technology.

What are the potential risks associated with excipient strategies?

Risks include:

• Regulatory delays for new excipient approvals.
• Supply chain disruptions for specialized excipients.
• Allergic reactions or intolerances.
• Increased development timelines for reformulated products.

Key Takeaways

• Excipient selection critically influences triampterene's stability, bioavailability, and patient compliance.
• Innovations such as controlled-release and dispersible formulations present commercial opportunities.
• Regulatory compliance and supply chain stability are key considerations.
• Formulation differentiation offers patent protection and market advantage.
• Tailoring excipient systems to regional needs supports global expansion.

FAQs

What excipients are most common in triampterene tablets?

Lactose monohydrate, microcrystalline cellulose, magnesium stearate, croscarmellose sodium, and film-forming agents.

How can excipient innovation extend product patent life?

By developing unique delivery systems or proprietary excipient combinations, companies can file new patents that protect formulations beyond the active ingredient.

Are there concerns about excipient-related hypersensitivity with triampterene?

Yes, lactose-based excipients can cause issues in lactose-intolerant patients. Alternatives like microcrystalline cellulose should be considered.

What regulatory hurdles exist for new excipients?

Approval requires comprehensive safety data and compliance with pharmacopeial standards. Novel excipients need additional toxicological studies.

How do environmental factors influence excipient choice?

High-humidity climates favor low-moisture excipients to maintain stability. Temperature-sensitive formulations require protective coatings or desiccants.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency. (2021). Guideline on the Use of Excipient Information in Medicinal Products.
[3] FDA. (2020). Chemistry, Manufacturing, and Controls (CMC) Considerations for Controlled-Release Drug Products.
[4] Sharma, R. et al. (2021). Advances in Excipient Technologies for Improved Drug Delivery. Journal of Pharmaceutical Sciences, 110(7), 2500-2510.